Sign in

CIK 0001395937 · Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
320162505
Phone
781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 4/A Option exercise President, Head of R&D acquired 73,673 shares (option exercise)
  2. 4 Open-market sale President, Head of R&D sold 104,173 shares at an average $17.48 ($1,820,735)
  3. DEFA14A Proxy Proxy Materials
  4. DEF 14A Proxy Proxy Statement
  5. SC 13D/A Stake Beneficial Ownership Report
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. S-8 Other Securities Offered to Employees in Benefit Plans
  9. 10-K Report Annual Report
  10. 8-K Event Results of operations · Executive or director change · Regulation FD disclosure
  11. 8-K Event Executive or director change
  12. SC 13G/A Stake Amended Statement of Ownership
  13. SC 13G Stake Amended Statement of Ownership
  14. SC 13G/A Stake Amended Statement of Ownership
  15. SC 13G/A Stake Amended Statement of Ownership
  16. SC 13G/A Stake Amended Statement of Ownership
  17. SC 13G/A Stake Amended Statement of Ownership
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market sale Chief Scientific Officer sold 1,412 shares at $16.65 ($23,510)

Page 14 of 33 · 660 filings